LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Accueil・Liste d'Actions・Design Therapeutics Inc

Design Therapeutics Inc

Fermé

10.55 0.96

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.19

Max

10.76

Chiffres clés
By Trading Economics
Revenu	-1.6M -18M
BPA	-0.29
Employés	54
EBITDA	-1.5M -20M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+87.38% upside

Dividendes
By Dow Jones
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-135M 665M
Ouverture précédente	9.59
Clôture précédente	10.55

Design Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 juin 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 juin 2026, 23:45 UTC

Acquisitions, Fusions, Rachats

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 juin 2026, 23:44 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 juin 2026, 23:44 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 juin 2026, 23:43 UTC

Acquisitions, Fusions, Rachats

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 juin 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 juin 2026, 22:06 UTC

Acquisitions, Fusions, Rachats

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 juin 2026, 22:05 UTC

Acquisitions, Fusions, Rachats

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 juin 2026, 20:51 UTC

Résultats

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juin 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juin 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 juin 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 juin 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 juin 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 juin 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 juin 2026, 18:52 UTC

Acquisitions, Fusions, Rachats

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 juin 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 juin 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 juin 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 juin 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 juin 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 juin 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juin 2026, 16:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juin 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 juin 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparaison

Variation de prix

Design Therapeutics Inc prévision

Objectif de Prix

By TipRanks

87.38% hausse

Prévisions sur 12 Mois

Moyen 19.6 USD 87.38%

Haut 22 USD

Bas 15 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.